| Title | Description | Host | Host Type | Outcomes |
|---|---|---|---|---|
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Apramycin use was 32 micrograms/mL | Swine | Sows | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Streptomycin use was 64 micrograms/mL | Swine | Piglets | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Tetracycline use 16 micrograms/mL | Swine | Sows | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Tetracycline use 16 micrograms/mL | Swine | Piglets | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Streptomycin use was 64 micrograms/mL | Swine | Sows | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Ampicillin use was 32 micrograms/mL | Swine | Sows | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Ampicillin use was 32 micrograms/mL | Swine | Piglets | 1 |
| Treatment | Treatment group was the use of Porcine-derived mucosal competitive exclusion vs. control. Apramycin use was 32 micrograms/mL | Swine | Piglets | 1 |